» Articles » PMID: 29492677

Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma

Overview
Journal Curr Oncol Rep
Publisher Current Science
Specialty Oncology
Date 2018 Mar 2
PMID 29492677
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Sinonasal mucosal melanoma (SNMM) is a rare oncological entity that comprises most head and neck mucosal melanomas. SNMM has distinctive genetic background, different from cutaneous melanoma. Survival outcomes among SNMM patients are poor; while there is no clear consensus on the optimal management of SNMM, the primary treatment modality is generally considered to be wide surgical excision, and radiation therapy (RT) is often used in the postoperative adjuvant setting to improve locoregional control. Systemic therapies have demonstrated little or no survival benefit, and most SNMM patients die of distant metastatic disease. Owing to the rarity of the disease, the literature describing treatment approaches for SNMM is lacking and largely limited to isolated case reports and retrospective series. Here, we describe contemporary diagnostic and therapeutic approaches to SNMM based on the most recent molecular and outcome data.

Citing Articles

Primary Sinonasal Mucosal Melanoma: A Narrative Review.

Todorovic N, Djurkovic P, Krstic A, Tomanovic N, Milanovic P, Kablar D Diagnostics (Basel). 2025; 15(4).

PMID: 40002647 PMC: 11854324. DOI: 10.3390/diagnostics15040496.


Ocular invasion in sinonasal malignant melanoma: A case report and review of literature.

Khademi B, Soltani S, Yousefi A, Heidari P, Mardani Z, Yousufzai S Int J Surg Case Rep. 2025; 127:110904.

PMID: 39842280 PMC: 11788794. DOI: 10.1016/j.ijscr.2025.110904.


Survival Outcomes in Sinonasal Mucosal Melanoma: Systematic Review and Meta-Analysis.

Rojas-Lechuga M, Jubes S, Molina-Garcia M, da Silva-Junior R, Sampieri C, Langdon C J Pers Med. 2024; 14(12).

PMID: 39728033 PMC: 11678336. DOI: 10.3390/jpm14121120.


Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.

Shan Z, Liu F Front Immunol. 2024; 15:1441410.

PMID: 39234260 PMC: 11373357. DOI: 10.3389/fimmu.2024.1441410.


Morphological and Immunohistochemical Aspects with Prognostic Implications and Therapeutic Targets of Primary Sinonasal Mucosal Melanoma: A Retrospective Study.

Trandafir C, Closca R, Poenaru M, Sarau O, Sarau C, Rakitovan M Cancers (Basel). 2024; 16(16).

PMID: 39199634 PMC: 11352549. DOI: 10.3390/cancers16162863.


References
1.
Kingdom T, Kaplan M . Mucosal melanoma of the nasal cavity and paranasal sinuses. Head Neck. 1995; 17(3):184-9. DOI: 10.1002/hed.2880170303. View

2.
Omholt K, Grafstrom E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding B . KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res. 2011; 17(12):3933-42. DOI: 10.1158/1078-0432.CCR-10-2917. View

3.
Gal T, Silver N, Huang B . Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011; 121(9):2026-33. DOI: 10.1002/lary.21925. View

4.
Khademi B, Bahranifard H, Nasrollahi H, Mohammadianpanah M . [Primary mucosal melanoma of the sinonasal tract: report of 18 patients and analysis of 1077 patients in the literature]. Braz J Otorhinolaryngol. 2011; 77(1):58-64. PMC: 9442177. DOI: 10.1590/s1808-86942011000100010. View

5.
Amit M, Laider-Trejo L, Shalom V, Shabtay-Orbach A, Krelin Y, Gil Z . Characterization of the melanoma brain metastatic niche in mice and humans. Cancer Med. 2013; 2(2):155-63. PMC: 3639654. DOI: 10.1002/cam4.45. View